U.S. stocks edge higher; solid earnings season continues
OneMedNet Corporation (NASDAQ:ONMD), a commercial physical and biological research services provider, has announced the appointment of Robert Golden as its interim Chief Financial Officer (CFO), effective today. The company's board of directors confirmed the appointment following the departure of Lisa Embree, who resigned from her role as CFO, Executive Vice President, Treasurer, and Secretary on Monday.
Golden, 62, brings over three decades of experience as a Certified Public Accountant to the position. He currently serves as the Managing Partner of Cohen, Bender & Golden LLP, offering consulting, accounting, and tax services.
Additionally, Golden holds CFO positions at Promo Shop, Inc. & Subsidiaries and iKahan Media, Inc. He has been a member of the Board of Directors of Talon International, Inc. (OTCMKTS: TALN) since 2013.
In conjunction with his new role, Golden has stepped down as a member and the chair of the Audit Committee of the Board. OneMedNet has entered into a consulting agreement with Golden, which includes a monthly salary of $12,000 and a grant of 100,000 restricted stock units. These units will vest on the first anniversary of the agreement, subject to its terms.
In other recent news, OneMedNet Corporation has made several significant strides. The company announced its transition from The Nasdaq Global Market to The Nasdaq Capital Market, a strategic move approved by Nasdaq's Listing Qualifications Department. This will not affect the trading symbols of OneMedNet's securities.
On the leadership front, the company bid farewell to board member Dr. Julianne Huh and welcomed Mr. Andrew B. Zeinfeld to its Board of Directors. The company also integrated artificial intelligence into its data curation process, leading to a reduction in operational costs and an increase in processing speed.
In financial developments, OneMedNet secured private funding of approximately $4.6 million from institutional investors, including affiliates of Off the Chain Capital and Discovery (NASDAQ:WBD) Capital Management.
The company also entered into a Standby Equity Purchase Agreement with investment firm Yorkville Advisors Global, LP, granting OneMedNet the option to sell up to $25 million of its common stock.
Finally, OneMedNet announced a new partnership through a Customer Data License Agreement with an undisclosed U.S.-based clinical trial design and software company. The company also joined the Amazon (NASDAQ:AMZN) Web Services (AWS) Partner Network (APN), securing a new client, a computational biotechnology firm.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.